Takeda, ENTYVIO, Vedolizumab, VERDICT Trial, Ulcerative Colitis, Inflammatory Bowel Disease, Gastroenterology, Phase 4 Clinical Trial, Treat-to-Target, Disease Clearance,

OSAKA, Japan, and CAMBRIDGE, Mass., October 19, 2026 Takeda (TSE: 4502; NYSE: TAK) announced new results from the Phase...